Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer.

[1]  E. Berns,et al.  BMC Cancer BioMed Central Research article Mismatch repair and treatment resistance in ovarian cancer , 2022 .

[2]  Frank Speleman,et al.  A novel and universal method for microRNA RT-qPCR data normalization , 2009, Genome Biology.

[3]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[4]  Janna Paulsson,et al.  Prognostic relevance of cancer-associated fibroblasts in human cancer. , 2014, Seminars in cancer biology.

[5]  A. Ullrich,et al.  Effects of interferons on the expression of the proto‐oncogene her‐2 in human ovarian carcinoma cells , 1992, International journal of cancer.

[6]  P. Roux,et al.  Cooperative Anti-Invasive Effect of Cdc42/Rac1 Activation and ROCK Inhibition in SW620 Colorectal Cancer Cells with Elevated Blebbing Activity , 2012, PloS one.

[7]  Steven A. Carr,et al.  The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices , 2011, Molecular & Cellular Proteomics.

[8]  A. Mes-Masson,et al.  Characterization of four novel epithelial ovarian cancer cell lines , 2000, In Vitro Cellular & Developmental Biology - Animal.

[9]  Edwin Cuppen,et al.  Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples , 2010, Nature Methods.

[10]  S. Kaye,et al.  The role of targeted therapy in ovarian cancer. , 2011, European journal of cancer.

[11]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[12]  D. Charnock-Jones,et al.  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[13]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[14]  R. Chen,et al.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.

[15]  S. Sleijfer,et al.  Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen , 2013, Breast Cancer Research and Treatment.

[16]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[17]  E. Berns,et al.  Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. , 2010, The international journal of biochemistry & cell biology.

[18]  H. Schuitemaker,et al.  cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. , 1988, Cancer research.

[19]  A. Ridley,et al.  RhoB regulates cell migration through altered focal adhesion dynamics , 2012, Open Biology.

[20]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[21]  Sheng-Chieh Hsu,et al.  Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. , 2007, Cancer research.

[22]  B. Sikic,et al.  Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. , 1991, Cancer research.

[23]  Kevin R Brown,et al.  Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.

[24]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[25]  S. Sleijfer,et al.  Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response , 2008, Clinical Cancer Research.

[26]  J. Trent,et al.  Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors. , 1983, Cancer research.

[27]  J. da Silva,et al.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.

[28]  H. Steed,et al.  Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. , 2013, Gynecologic oncology.

[29]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[30]  J. Foekens,et al.  Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer , 2013, Breast Cancer Research and Treatment.

[31]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[32]  J. Trent,et al.  Comparative properties of five human ovarian adenocarcinoma cell lines. , 1985, Cancer research.

[33]  E. Zwarthoff,et al.  Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes , 2010, PloS one.

[34]  A. Merlo,et al.  Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme , 2013, Oncogene.

[35]  Alexandra Naba,et al.  Overview of the matrisome--an inventory of extracellular matrix constituents and functions. , 2012, Cold Spring Harbor perspectives in biology.

[36]  CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival , 2012, Clinical & Experimental Metastasis.

[37]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Weidong Yu,et al.  Sorting and identification of side population cells in the human cervical cancer cell line HeLa , 2014, Cancer Cell International.

[39]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[40]  Mina J Bissell,et al.  The tumor microenvironment is a dominant force in multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[41]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[42]  R. Price,et al.  Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. , 2007, Neoplasia.

[43]  S. Shah,et al.  Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research , 2013, PloS one.

[44]  B. Sikic,et al.  Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. , 1990, Cancer research.

[45]  T. Orfeo,et al.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. , 1977, Journal of the National Cancer Institute.

[46]  J. Whang‐Peng,et al.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. , 1983, Cancer research.

[47]  A. Whetton,et al.  The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. , 2014, Cancer treatment reviews.

[48]  R. Berkowitz,et al.  Differential hRad17 expression by histologic subtype of ovarian cancer , 2011, Journal of ovarian research.

[49]  A. Fattorossi,et al.  Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts , 2011, Cancer Chemotherapy and Pharmacology.

[50]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[51]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[52]  Zhaogang Dong,et al.  N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines , 2013, PloS one.

[53]  N. Ueno,et al.  Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. , 2011, Gynecologic oncology.

[54]  W. Weichert,et al.  Genotypic and phenotypic characterization of side population of gastric cancer cell lines. , 2011, The American journal of pathology.

[55]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[56]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[57]  E. Cuppen,et al.  Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. , 2014, The Journal of allergy and clinical immunology.

[58]  B. Jiang,et al.  Fas signaling promotes motility and metastasis through epithelial–mesenchymal transition in gastrointestinal cancer , 2013, Oncogene.

[59]  E. Giannoni,et al.  EphA2 Induces Metastatic Growth Regulating Amoeboid Motility and Clonogenic Potential in Prostate Carcinoma Cells , 2011, Molecular Cancer Research.

[60]  Teri A. Crosby,et al.  How to Detect and Handle Outliers , 1993 .

[61]  M. Bookman.  First line therapy: have we made any improvement? , 2011, European journal of cancer.

[62]  A. Hagemeijer,et al.  Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: Growth features and cytogenetics , 1993, International journal of cancer.

[63]  C. Wolf,et al.  Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient , 1987, International journal of cancer.

[64]  A. Wilson.  Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. , 1984, Journal of the National Cancer Institute.

[65]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[66]  D. Bowtell,et al.  Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. , 2013, European journal of cancer.

[67]  A. Mes-Masson,et al.  Mapping of chromosome 3p deletions in human epithelial ovarian tumors , 1998, Oncogene.

[68]  E. Cuppen,et al.  Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing , 2011, Nature Protocols.

[69]  Christopher Korch,et al.  DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. , 2012, Gynecologic oncology.

[70]  J. Foekens,et al.  Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations , 2010, Breast Cancer Research and Treatment.

[71]  R C Young,et al.  Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. , 1984, Seminars in oncology.

[72]  M. Quinn,et al.  Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile , 2011, Journal of cellular biochemistry.

[73]  T. Pejović,et al.  Characterisation of seven human ovarian tumour cell lines. , 1996, British Journal of Cancer.

[74]  V. Zurawski,et al.  Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. , 1988, Gynecologic oncology.

[75]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[76]  T. H. van der Kwast,et al.  FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy , 2010, PloS one.

[77]  Y. Ohta,et al.  FilGAP, a Rho/Rho-associated protein kinase–regulated GTPase-activating protein for Rac, controls tumor cell migration , 2012, Molecular biology of the cell.

[78]  Rochelle L. Garcia,et al.  Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation , 2007, Molecular Cancer Research.

[79]  Ie-Ming Shih,et al.  Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[80]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[81]  E. Berns,et al.  Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. , 2010, Gynecologic oncology.

[82]  D. Bowtell,et al.  The changing view of high-grade serous ovarian cancer. , 2012, Cancer research.

[83]  Anil K Sood,et al.  Early events in the pathogenesis of epithelial ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  L. Kèlland,et al.  Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. , 1989, British Journal of Cancer.

[85]  Maurice P H M Jansen,et al.  Molecular profiling of platinum resistant ovarian cancer , 2006, International journal of cancer.

[86]  J. Smyth,et al.  Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.